SCM
CATX icon

Sterling Capital Management’s Perspective Therapeutics CATX Stock Holding History

Sterling Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.1K Buy
2,081
+9
+0.4% +$34 ﹤0.01% 2419
2026
Q1 		$8.64K Sell
2,072
-1,363
-40% -$5.76K ﹤0.01% 2455
2025
Q4 		$9.45K Sell
3,435
-677
-16% -$1.93K ﹤0.01% 2633
2025
Q3 		$14.1K Buy
4,112
+2,503
+156% +$9.13K ﹤0.01% 2311
2025
Q2 		$5.54K Buy
1,609
+1,386
+622% +$3.66K ﹤0.01% 2448
2025
Q1 		$475 Sell
223
-168
-43% -$504 ﹤0.01% 2963
2024
Q4 		$1.25K Buy
391
+324
+484% +$2.65K ﹤0.01% 2896
2024
Q3 		$894 Buy
+67
New +$891 ﹤0.01% 2589

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Sterling Capital Management's CATX Position: Q2 2026 in Review

Sterling Capital Management increased its Perspective Therapeutics (CATX) stake by 0.43% in Q2 2026, buying an estimated $34 and bringing the position to 2,081 shares worth $7.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2419.

Sterling Capital Management first reported a position in CATX in Q3 2024 and has held it in 8 quarters since. The position peaked at $14.1K in Q3 2025. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Sterling Capital Management held 2,081 shares of Perspective Therapeutics worth $7.1K as of Q2 2026.
  • Sterling Capital Management bought 9 Perspective Therapeutics shares in Q2 2026, an estimated $34.
  • Perspective Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2419 holding.
  • Sterling Capital Management first reported a position in Perspective Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Perspective Therapeutics position peaked at $14.1K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.